drugset / Trial / NCT07414992
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
Phase 2
Not yet recruiting
44 enrolled
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for people with muscle-invasive bladder cancer (MIBC).
Timeline
- Start
- 2026-07
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | — |
| Subject | Fianlimab | Monoclonal antibody | — | — |